The FDA is look­ing to dis­pel what it says are in­ac­cu­rate claims that it's in­creas­ing­ly re­ject­ing new drugs af­ter an ini­tial re­view.

The claims stem...

There aren’t any easy an­swers around Chi­na and biotech.

End­points Newstook our Chi­na de­bate on the road to DC this week. We sat down...

No­vo won reg­u­la­to­ry back­ing for its he­mo­phil­ia A pre­ven­tive drug from the Eu­ro­pean Med­i­cines Agen­cy's hu­man med­i­cines com­mit­tee, which al­so rec­om­mend­ed ap­prov­ing sev­en oth­er new...

Elec­tra Ther­a­peu­tics be­came the 21st biotech of 2026 to go through with an IPO af­ter pric­ing its $350 mil­lion Nas­daq de­but on Thurs­day evening.

The Bay...

Any doubts about Chi­na’s am­bi­tions as a ma­jor glob­al com­peti­tor in bio­phar­ma are quick­ly dis­ap­pear­ing.

On Fri­day, the Chi­nese gov­ern­ment is­suedthe lat­est five-year plan...

When it made its much-hyped Mythos avail­able back on Ju­ly 1, An­throp­ic said the AI mod­el was so pow­er­ful it could­n't al­low the tech­nol­o­gy to...